NeuroSense reports significant survival benefit with PrimeC in ALS trial
NeuroSense reported updated long-term results from its completed Phase 2b PARADIGM trial of PrimeC in ALS, showing an estimated median survival of 36.3 months for continuously treated patients versus 21.4 months for those initially randomized to placebo. PrimeC is an investigational extended-release oral formulation combining two FDA-approved drugs, and NeuroSense says the survival data support advancing the therapy into pivotal late-stage development and deeper regulatory engagement.
Why it mattersPhase 2b ALS survival benefit (36.3 vs 21.4 months) supports accelerating pivotal trial planning and regulatory engagement.